Alzheimer's biochip blood test as accurate as molecular Dx

Brain imaging

A new biochip-based blood test can help identify patients at a higher risk for Alzheimer’s disease just as accurately as the standard molecular diagnostic test. Researchers from Randox Laboratories presented study results Wednesday at the annual meeting of the American Association for Clinical Chemistry.

The biochip, which allows multiple tests to be conducted on one blood sample, works by detecting a protein produced by a variant of the gene apolipoprotein (ApoE4) that is linked to an elevated risk of developing Alzheimer’s. A patient who inherits the ApoE4 gene from one parent he or she is three times more likely to develop the disease, while one who inherits it from both parents is 8 to 12 times more likely to develop it, according to a statement.

The study pitted the biochip test against the standard molecular diagnostic test. The Randox team worked with researchers from the Medical University of Vienna to analyze 384 results using both methods. The results were “in 100% agreement,” they said in the statement.

Event

Join the world's top medtech executives virtually for the leading event in medtech — The Virtual MedTech Conference by AdvaMed

Expect the same high-quality education, world-class speakers and valuable business development in a virtual format. Experience more of the conference with on demand content and partnering, as well as livestreamed sessions.

While the tests are equally effective, the biochip test is cheaper, allows physicians to run multiple tests at once and delivers results within three hours.

"Pairing this test with medical and family history for risk of Alzheimer's disease has the real potential to advance personalized medicine," said Emma Harte, a research scientist at Randox, in the statement. "This fast, accurate testing will allow doctors and patients to make more informed choices earlier to potentially slow the possible progress of Alzheimer's."

Randox is not the only company seeking an alternative diagnostic for the neurodegenerative disease. In June, Sacramento-based NeuroVision raised $10 million to advance its retinal imaging technology for the early detection of Alzheimer’s, while New York’s Cerebral Assessment Systems is developing a video game-like tool to screen for early signs of the disease.

- here's the statement
- see the presentation abstract

Related Articles:
NeuroVision raises $10M to advance retinal diagnostic for Alzheimer's
New York startup trots out video game-like screening device for Alzheimer's
Cytox debuts genetic biomarker research tool to test for Alzheimer’s risk
Amarantus scores a small victory in the advance of its Alzheimer's Dx test

Read more on

Suggested Articles

Ironwood had once hyped this drug as a $2 billion-a-year asset, but IW-3718 has failed to live up to its high expectations.

The company describes the continuous glucose monitor as the world’s smallest and thinnest diabetes sensor, with a disc about the size of two pennies.

Junshi’s PD-1 blocker is already approved in China for metastatic melanoma, but the Shanghai-based biotech may soon add throat cancer to its label.